参考文献/References:
[1] 郭家毓,呼群.小细胞肺癌免疫治疗研究进展[J].陕西医学杂志,2023,52(1):118-121.
[2] MELANIE R,RUTKOWSKI,TOM L.Anti-tumor immunity:Myeloid leukocytes control the immune landscape[J].Cell Immunol,2012,278:21-26.
[3] 梁乐乐,王鹏,刘俊霞.非小细胞肺癌组织中T细胞免疫球蛋白区黏蛋白-3、程序性死亡因子-1及程序性因子配体1的表达分析[J].陕西医学杂志,2021,50(10):1227-1230.
[4] KUMAGAI S,KOYAMA S,ITAHASHI K,et al.Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments[J].Cancer Cell,2022,40(2):201-218.
[5] HUANG J,LIU D,WANG Y,et al.Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio,potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1(anti-PD-1/PD-L1)immunotherapy[J].Gut,2022,71(4):734-745.
[6] SHARMA P,ALLISON J P.The future of immune checkpoint therapy[J].Science,2015,348(6230):56-61.
[7] BHARDWAJ M,CHIU M N,PILKHWAL S S.Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors:Pathogenesis,treatment,and surveillance[J].Cutan Ocul Toxicol,2022,41(1):73-90.
[8] HONG L,AMINU M,LI S,et al.Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer[J].Nat Commun,2023,14(1):695-709.
[9] PETRELLI F,FERRARA R,SIGNORELLI D,et al.Immune checkpoint inhibitors and chemotherapy in first-line NSCLC:A meta-analysis[J].Immunotherapy,2021,13(7):621-631.
[10] READY N,HELLMANN M D,AWAD M M.First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer(CheckMate 568):Outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers[J].J Clin Oncol,2019,37(12):992-1000.
[11] SUNDAR R,SOONG R,CHO B C.Immunotherapy in the treatment of non-small cell lung cancer[J].Lung Cancer,2014,85(2):101-109.
[12] RECK M,RODRIGUEZ A D,ROBINSON A G.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J].N Engl J Med,2016,375(19):1823-1833.
[13] 周彩存,王洁,步宏.中国非小细胞肺癌免疫检查点抑制剂治疗专家共识(2019年版)[J].中国肺癌杂志,2020,23(2):65-76.
[14] LANGER C J,GADGEEL S M,BORGHAEI H.Carboplatin and pemetrexed with or without pembrolizumab for advanced,non-squamous nonsmall-cell lung cancer:A randomised,phase 2 cohort of the open-label KEYNOTE-021 study[J].Lancet Oncol,2016,17(11):1497-1508.
[15] 孙丽,刘臻,张述.免疫检查点抑制剂治疗相关不良反应及处理[J].医学研究生学报,2019,32(10):1115-1120.
[16] 侯佳奇,薛鸾.原发性干燥综合征发病机制概述[J].现代免疫学,2019,39(1):58-63.
[17] HOLLERN D P,XU N,THENNAVAN A,et al.B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer[J].Cell,2019,179(5):1191-1206.
[18] NAIDOO J,WANG X,WOO K M.Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J].J Clin Oncol,2017,35(7):709-717.
[19] GARON E B,RIZVI N A,HUI R.Pembrolizumab for the treatment of non-small-cell lung cancer[J].N Engl J Med,2015,372(21):2018-2028.
[20] KATO T,MASUDA N,NAKANISHI Y.Nivolumab-induced interstitial lung disease analysis of two phase Ⅱ studies patients with recurrent or advanced non-small-cell lung cancer[J].Lung Cancer,2017,104(2017):111-118.
[21] HAANEN J,CARBONNEL F,ROBERT C.Management of toxicities from immunotherapy:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2018,29(14):264-266.
[22] 彭智,袁家佳,王正航.ASCO/NCCN免疫治疗毒性管理指南解毒[J].肿瘤综合治疗电子杂志,2018,4(2):38-47.
[23] 薛鹏,徐芃芃,毛昀.非小细胞肺癌免疫检查点抑制剂相关性肺炎研究进展[J].中国肿瘤,2019,28(5):367-372.
[24] NISHINO M,SHOLL L M,HODI F S.Anti-PD-1-related pneumonitis during cancer immunotherapy[J].N Engl J Med,2015,373(3):288-290.
[25] 夏燕婷,王淑静,韦企平,等.中药参与糖皮质激素治疗视神经炎的临床探讨[J].中国中医眼科杂志,2020,30(12):885-887.
[26] 吴雪,张惜燕,李翠娟.固本活血壮骨颗粒通过Wnt/LRP5/β-catenin信号通路改善糖皮质激素性骨质疏松症机制研究[J].陕西中医,2023,44(12):1693-1697.
[27] 徐红日,李雅莉,王成祥.黄芩对流感病毒FM1感染所致病毒性肺炎小鼠肺中炎性细胞因子蛋白与基因表达的影响[J].中国中药杂志,2019,44(23):5166-5173.
[28] 徐红日,王成祥,王兰.益气清瘟解毒合剂所含益气法中药抗流感免疫炎性损伤的机制[J].中国中药杂志,2014,39(20):4020-4026.
[29] 王昱,李耀辉.抗纤汤联合醋酸泼尼松片治疗类风湿关节炎合并肺间质病变气虚血瘀证疗效研究[J].陕西中医,2023,44(4):463-466.
[30] 李玉安,武生梅.自拟清肺饮治疗间质性肺炎[J].长春中医药大学学报,2014,10(5):890-891.
[31] 张雪梅.自拟达络肺仙饮治疗特发性间质性纤维化的临床观察[J].云南中医中药杂志,2014,35(7):28-29.